Monday, October 17, 2022 from 3:30 PM to 5:00 PM PDT at Continental Ballroom 4
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-22-174-L01-P
Activity Type: An Application-Based Activity
This session focuses on the management of Alzheimer’s Disease. Specific topics will include 1) an overview of Alzheimer’s Disease and Mild Cognitive Impairment with an emphasis on current standards of care and associated challenges in care; 2) a discussion of clinical data regarding adjunctive and novel therapies in the management of Alzheimer’s Disease and Mild Cognitive Impairment and 3) a dialogue about real-world considerations in the utilization of novel medication therapies for Alzheimer’s Disease and Mild Cognitive Impairment. The target audience of this session is practicing pharmacists, pharmacy residents, pharmacy students, and associated medical professionals. The purpose of this session is to deliver education for an evolving, relevant issue to enhance pharmacist understanding and readiness in application to the clinical setting.
Learning Objectives
1. Discuss the key features of Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) including course of illness and implications for patient care.
2. Describe the current standards of care in the management of AD and MCI.
3. Analyze the clinical data surrounding investigational, adjunctive, and novel therapies in the management of AD and MCI.
4. Evaluate potential challenges and real-world considerations in the application of novel medication therapies in the care of patient’s living with AD or MCI.
5. Apply evidence-based medicine describing novel medication therapies to optimize the care of patient’s living with AD or MCI.